GAITHERSBURG, Md., Nov. 4, 2015 /PRNewswire/ — GenVec, Inc. (NASDAQ: GNVC), a clinical-stage gene delivery company, announced that Douglas E. Brough, Ph.D., the company’s chief scientific officer, has given a presentation entitled “Gorilla Adenovirus Vectors for Molecular Therapeutics and Vaccines” at the Vaccines R&D-2015 Conference in Baltimore taking place November 2-4. The presentation highlighted the differentiated and superior performance characteristics seen with GenVec’s gorilla adenovectors for molecular vaccines, which have been shown to generate strong, durable antibody and T cell responses to an encoded antigen after a single administration.
Most recently, GenVec has combined its gorilla adenovectors with novel malaria antigens and protein vaccine approaches developed by Patrick E. Duffy, M.D. and colleagues at the Laboratory of Malaria Immunology and Vaccinology (LMIV). LMIV is part of the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health. The experimental vaccine combination produced promising results in preclinical models designed to test vaccine candidates that are designed to block transmission of malaria parasites by carrier mosquitoes.
“These preclinical data generated by our collaborators show high levels of durable antibody responses to LMIV’s antigens. These antibodies can be taken up by a mosquito when it bites a vaccinated individual and stop oocyst generation, neutralizing the parasite and blocking further transmission,” said Dr. Brough.